OPEN ACCESS **MOLECULES** ISSN 1420-3049 www.mdpi.com/journal/molecules

Article

Hexachlorocyclotriphosphazene (HCCP)-Mediated Direct Formation of Thioethers and Ethers from Quinazolin-4(3*H*)-ones

Baoxiang Hu¹, Xiaochu Zhang¹, Lili Sheng¹, Ming Guo², Zhenlu Shen^{1,*}, Xinquan Hu¹, Nan Sun¹ and Weimin Mo^{1,*}

- ¹ State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology, College of Chemical Engineering and Materials Science, Zhejiang University of Technology, Hangzhou 310014, China
- ² Department of Chemistry, Zhejiang Agriculture & Forestry University, Lin'An 311300, China
- * Authors to whom correspondence should be addressed; E-Mails: zhenlushen@zjut.edu.cn (Z.S.); mowm@zjut.edu.cn (W.M.); Tel.: +86-571-8832-0416 (Z.S.); Fax: +86-571-8832-0103 (Z.S.).

Received: 25 March 2013; in revised form: 12 May 2013 / Accepted: 13 May 2013 / Published: 15 May 2013

Abstract: A hexachlorocyclotriphosphazene (HCCP)-mediated direct formation of quinazoline (thio)ethers from quinazolin-4(3H)-ones has been developed. Treatment of quinazolin-4(3H)-ones with HCCP, diisopropylethylamine (DIPEA), and thiophenols resulted in formation of the corresponding 4-arylthioquinazoline derivatives in moderate to excellent yields. This method has also been utilized to prepare 4-aryloxyquinazoline and 4-alkoxyquinazoline derivatives using phenols and sodium alkoxides as the nucleophiles.

Keywords: quinazolin-4(3*H*)-ones; hexachlorocyclotriphosphazene; 4-arylthioquinazolines; 4-aryloxyquinazolines; 4-alkoxyquinazolines

1. Introduction

Quinazoline derivatives are an important class of nitrogen-containing heterocycles. They have attracted interest in the past because of their varied biological activities, such as anticonvulsant, antihypertensive, vasodilator, antiinflammatory, antibiosis, fibrinogen receptor antagonistic and nanomolar Hedgehog-antagonistic properties [1–8]. Among the family of quinazolines, quinazoline (thio)ethers, including 4-arylthioquinazolines and 4-aryloxyquinazolines, have received considerable interest because of their potential pharmacological activity [9–16].

Generally, 4-arylthioquinazolines and 4-aryloxyquinazolines are obtained through S_NAr substitution of electron-deficient 4-chloroquinazolines with the appropriate thiophenols or phenols in the presence of a base [9–19]. The common method for preparation of 4-chloroquinazolines is the chlorination of corresponding quinazolin-4(3*H*)-ones. The chlorination reagents used include SOCl₂, POCl₃, PCl₅ or their combinations, and the chlorination reactions are usually performed under harsh conditions. However, these chlorination reagents are not environmentally friendly, and some sensitive functional groups may be destroyed under the chlorination conditions. In addition, many 4-chloroquinazoline derivatives are moisture sensitive, thus special treatments are required for their purification and storage.

In order to avoid the use of chlorination reagents and an individual activation step, an *in situ* activation of quinazolin-4(3*H*)-ones is highly desirable. Phosphonium compounds, such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), have been developed to activate quinazolin-4(3*H*)-ones and successfully employed in the synthesis of 4-aminoquinazolines, 4-arylthioquinazolines and 4-aryloxyquinazolines using amine, thiophenol and phenol nucleophiles, respectively [20,21]. However, BOP and other phosphonium reagents are expensive, moreover, utilization of BOP generates as an end product HMPA, a highly carcinogenic chemical.

As a part of our research program focused on quinazoline chemistry [22,23], we have recently, reported that hexachlorocyclotriphosphazene ($Cl_6N_3P_3$, HCCP) can be used as an inexpensive and readily available activating reagent in the direct amination of quinazolin-4(*3H*)-ones (1) [24]. In the reaction, quinazolin-4(*3H*)-ones are activated *in situ* with HCCP to generate the highly reactive phosphonium intermediate 2, then amines can nucleophilically attack 2 to form 4-aminoquinazolines. Thus, we speculated that other nucleophiles, such as thiophenol and phenol ones, might attack 2 to form the corresponding products. Herein, we report a HCCP-mediated, single-pot, facile synthesis of thioethers and ethers from quinazolin-4(*3H*)-ones in moderate to excellent yields (Scheme 1).

Scheme 1. One-pot synthesis of quinazoline (thio)ethers from quinazolin-4(3*H*)-ones mediated by HCCP.



2. Results and Discussion

Initially, the reaction of quinazolin-4(3H)-one (1a) and thiophenol was investigated as the model reaction to establish the feasibility of the strategy and to optimize the reaction conditions. The effects of solvent, base, temperature and HCCP loading, *etc.*, were evaluated for this model reaction, and the results are summarized in Table 1.

		NH HCCP, base, solvent PhSH		
Entry	Base	Solvent	Temperature (°C)	Yield (%) ^b
1	TEA	MeCN	45	48
2	K_2CO_3	MeCN	45	32
3	Cs_2CO_3	MeCN	45	69
4	DIPEA	MeCN	45	81
5	DIPEA	THF	45	12
6	DIPEA	DMF	45	23
7	DIPEA	CH_2Cl_2	45	7
8	DIPEA	MeCN	45	76 °
9	DIPEA	MeCN	25	68
10	DIPEA	MeCN	65	55
11	DIPEA	MeCN	45	79 ^d
12	DIPEA	MeCN	45	71 ^e
13	DIPEA	MeCN	45	81 ^f
14	DIPEA	MeCN	45	70 ^g

Table 1. Optimization of reaction conditions^a.

^a Conditions: **1a** (0.5 mmol), HCCP (1.1 equiv.), base (5.0 equiv.), solvent (5 mL), rt, activation time (1 h), then thiophenol (6.0 equiv.), 45 °C, 23 h; ^b Isolated yield; ^c HCCP (1.0 equiv.); ^d Thiophenol (5.0 equiv.); ^e Thiophenol (4.0 equiv.); ^f DIPEA (6.0 equiv.); ^g DIPEA (4.0 equiv.).

Compared with triethylamine (TEA), K_2CO_3 and Cs_2CO_3 (entries 1–3), diisopropylethylamine (DIPEA) was found to be the most effective in the model reaction of 1a and thiophenol (entry 4). The results in Table 1 show that the solvent can greatly affect the reaction, and acetonitrile led to much better yield of product 3 than tetrahydrofuran, N,N-dimethylformamide or dichloromethane (entries 4–7). According to Scheme 1, 1.0 equiv. HCCP loading was enough, but we found that increasing the HCCP loading from 1.0 to 1.1 equiv. resulted in 5% yield increases (entry 8 versus entry 4). After in situ activation of **1a** with HCCP at room temperature for 1 h, the S_NAr substitution of phosphonium intermediate 2a ($R^1 = H$) with thiophenol was performed at 45 °C. At both lower and higher temperature, the yield of 3 decreased (entries 9 and 10). Like the HCCP-mediated direct amination of quinazolin-4(3H)-ones with amines [24], when the thiophenol nucleophile attacks 2a, two competitive S_NAr substitutions were possible, either on the C–O bond or P–Cl bond. Thus, five to six equiv. of thiophenol and DIPEA were needed in this reaction. It was found variation of the amount of thiophenol or DPIEA from 6.0 equiv. to 5.0 equiv. did not significantly change the results (entry 4 versus entries 11 and 13), whereas upon decreasing the amount of thiophenol or DPIEA to 4.0 equiv., the yield of 3 was obviously decreased (entries 12 and 14). On the basis of these experimental data, the optimal reaction conditions were: 1.1 equiv. of HCCP, 5.0 equiv. of DIPEA, 5.0 equiv. of thiophenol, 45 °C of reaction temperature and acetonitrile as the reaction solvent, and these were employed in the following studies.

The results of HCCP-mediated direct formation of thioethers (4-arylthioquinazolines) from 1 and thiophenols are summarized in Table 2. Different substituted thiophenols smoothly reacted with 1a to afford the desired 4-arylthioquinazolines in moderate to excellent yields (entries 1–9). When o, m, and p-methoxythiophenols were used as the nucleophiles, o-methoxythiophenol gave the highest product yield, while m-methoxythiophenol showed the lowest reactivity (entries 4–6). It is noteworthy that chlorothiophenols, which usually exhibit lower nucleophilicity than methoxythiophenols, could conveniently undergo the transformation and gave excellent product yields in this HCCP-mediated direct formation of 4-arylthioquinazolines (entries 7 and 9). The reactions between thiophenol and a variety of substituted quinazolin-4(3H)-ones were also investigated. An array of substituted quinazolin-4(3H)-ones in moderate to good yields (entries 1, 10–15). When 5-methylquinazolin-4(3H)-one (1b) and 5-chloroquinazolin-4(3H)-one (1e) were used as the substrates, activation time should be prolonged (entries 10 and 13).





Table 2. Cont.

Entry	Quinazolin-4(3H)-oi	ne	ArSH	Product		Yield (%) ^b
5	1a		SH OCH ₃	S OCH ₃	7	50
6	1 a		CH ₃ O	S N N	8	86
7	1a		CI SH	S N CI	9	94
8	1a		CI SH	S CI	10	66
9	1a		CI	S N N	11	91
10		1b	SH		12	54 ^d
11	O NH	1c	SH	S N N	13	60
12	O NH	1d	SH	S N N	14	64

 Table 2. Cont.



^a *Reagents and Conditions*: **1** (0.5 mmol), HCCP (1.1 equiv.), DIPEA (5.0 equiv.), MeCN (5 mL), rt, activation time (1 h), then thiophenols (5.0 equiv.), 45 °C, 23 h; ^b Isolated yield; ^c *m*-CH₃PhSH (6.0 equiv.); reaction time (48 h); ^d Activation time (20 h).

The method was further extended to the synthesis of 4-aryloxyquinazolines through the reaction of **1** and phenols under the same reaction conditions (Table 3). Different phenols (phenol, *m*-methylphenol, *o*-chlorophenol and *p*-chlorophenol) could react with **1a** and afforded the corresponding products **18–21** in moderate to good yields (entry 1–5). There is no significant electronic effect of substituents for products. Substituted quinazolin-4(3*H*)-ones were also used as the substrates to react with phenol. 6-Chloroquinazolin-4(3*H*)-one (**1f**) and 7-chloroquinazolin-4(3*H*)-one (**1g**) gave products **14** and **15** in 70% yield (entries 6 and 7), whereas in the case of 5-methylquinazolin-4(3*H*)-one (**1b**), the product **12** was obtained in 54% yield (entry 5). Alcohols were also used as the nucleophiles in this reaction. Unfortunately, no desired 4-alkoxyquinazolines were formed. It might be due to that the nucleophilicity of alcohols was too weak to undego S_NAr substitution. Thus, sodium alkoxides were further utilized as the nucleophiles in this reaction to give the corresponding 4-alkoxyquinazolines (Table 3). When **1a**, 8-methylquinazolin-4(3*H*)-one (**1d**) and **1g** reacted with sodium ethoxide for 3 h, the yields of products 4-ethoxyquinazolines were 54%, 64% and 67%, respectively (entries 8,10 and 11), while **1b** gave only 33% product yield (entry 9). 4-Propoxyquinazoline (**29**) could be obtained in 48% yield in the reaction between **1a** and sodium propoxide (entry 12).





Entry	Quinazolin-4(3 <i>H</i>)-one	ArOH or RONa	Product		Yield (%) ^b
1	1a	OH		18	75
2	1 a	OH		19	52
3	1a	OH CI		20	73
4	1 a	CI		21	51
5	1b	OH		22	53 °
6	1f	OH		23	70
7	1g	OH		24	70
8	1a	CH ₃ CH ₂ ONa		25	54

Table 3. Cont.

Entry	Quinazolin-4(3H)-one	ArOH or RONa	Product	Yield (%) ^b
9	1b	CH ₃ CH ₂ ONa	O N N	26 33 °
10	1d	CH ₃ CH ₂ ONa		27 67
11	1g	CH ₃ CH ₂ ONa		28 64
12	1a	CH ₃ CH ₂ CH ₂ ONa		29 48

^a *Reagents and Conditions*: **1** (0.5 mmol), HCCP (1.1 equiv.), DIPEA (5.0 equiv.), MeCN (5 mL), rt, activation time (1 h), then phenols (5.0 equiv.), 45 °C, 23 h; or R²ONa (5.0 equiv.), 45 °C, 3 h; ^b Isolated yield; ^c Activation time (20 h).

3. Experimental

3.1. General

¹H-NMR (500 MHz) and ¹³C-NMR (125 MHz) spectra were obtained on a Bruker Avance III spectrometer. CDCl₃ and DMSO- d_6 were used as the solvent with tetramethylsilane (TMS) as the internal standard. Low and high resolution mass spectra were recorded in the ESI mode on an Agilent 6210 LC/TOF mass spectrometer. Melting points were measured using XRL-1 melting point instrument and are uncorrected. Quinazolin-4(3*H*)-ones were synthesized from anthranilic acids and formamidine acetate, and their structures were confirmed by MS, ¹H-NMR, and ¹³C-NMR. Other reagents were purchased from supplier and used without any further treatment.

3.2. General Procedure for HCCP-Mediated Formation of Thioethers and Ethers from *Quinazolin-4(3H)-ones*

Quinazolin-4(3*H*)-ones (1, 0.5 mmol), HCCP (171.2 mg, 0.55 mmol, 1.1 equiv.), DIPEA (323.8 mg, 2.5 mmol, 5 equiv.), and CH₃CN (5 mL) were added to a nitrogen purged vial. The reaction mixture was stirred at room temperature for 1 h as activation time. Then nucleophile (2.5 mmol, 5 equiv. was added, and the reaction mixture was stirred at 45 °C for 23 h. The reaction mixture was partially concentrated under reduced pressure. The crude product was separated on a silica gel plate with ethyl acetate–hexane (1:10 or 1:5) as eluent. Then the area corresponding to the product was scraped off the

TLC plate, and extracted with dichloromethane. The extract was concentrated to afford the corresponding products (3–29).

4-(Phenylthio)quinazoline (**3**). White solid (79% yield); mp 109–110 °C; ¹H-NMR (DMSO-*d*₆) δ 8.84 (s, 1H), 8.27 (d, *J* = 8.5 Hz, 1H), 8.07–8.04 (m, 1H), 8.00–7.99 (m, 1H), 7.83–7.79 (m, 1H), 7.68–7.66 (m, 2H), 7.56–7.54 (m, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.3, 153.5, 147.8, 135.8, 134.6, 129.9, 129.6, 128.5, 128.4, 126.5, 123.6, 122.3; HRMS (ESI), *m/z*, 239.0644 [MH⁺], calcd for C₁₄H₁₁N₂S, 239.0643.

4-(m-Tolylthio)quinazoline (**4**). White solid (64% yield); mp 58–61 °C; ¹H-NMR (DMSO-*d*₆) δ 8.83 (s, 1H), 8.25 (d, *J* = 8.0 Hz, 1H), 8.05–8.02 (m, 1H), 7.99–7.97 (m, 1H), 7.81–7.77 (m, 1H), 7.48–7.41 (m, 3H), 7.36–7.35 (m, 1H), 2.37 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.5, 153.5, 147.8, 139.0, 136.0, 134.6, 132.9, 130.6, 129.4, 128.5, 128.3, 126.2, 123.6, 122.4, 20.7; HRMS (ESI), *m/z*, 253.0795 [MH⁺], calcd for C₁₅H₁₃N₂S, 253.0799.

4-(p-Tolylthio)quinazoline (**5**) White solid (69% yield); mp 104–105 °C; ¹H-NMR (DMSO-*d*₆) δ 8.81 (s, 1H), 8.19 (d, *J* = 8.0 Hz, 1H), 8.02–7.98 (m, 1H), 7.96–7.95 (m, 1H), 7.77–7.73 (m, 1H), 7.50–7.48 (m, 2H), 7.31 (d, *J* = 8.0 Hz, 2H), 2.38 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.6, 153.4, 147.7, 139.7, 135.7, 134.4, 130.1, 128.4, 128.2, 123.4, 122.9, 122.3, 20.8; HRMS (ESI), *m/z*, 253.0798 [MH⁺], calcd for C₁₅H₁₃N₂S, 253.0799.

4-(2-Methoxyphenylthio)quinazoline (**6**). White solid (59% yield); mp 111–113 °C; ¹H-NMR (DMSO-*d*₆) δ 8.80 (s, 1H), 8.27 (d, *J* = 8.0 Hz, 1H), 8.04–8.01 (m, 1H), 7.98–7.96 (m, 1H), 7.80–7.76 (m, 1H), 7.60–7.54 (m, 2H), 7.20 (d, *J* = 8.0 Hz, 1H), 7.10–7.07 (m, 1H), 3.74 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.0, 160.0, 153.5, 147.8, 137.5, 134.4, 132.2, 128.4, 128.2, 123.7, 122.5, 121.2, 114.2, 112.3, 55.9; HRMS (ESI), *m/z*, 269.0747 [MH⁺], calcd for C₁₅H₁₃N₂OS, 269.0749.

4-(3-Methoxyphenylthio)quinazoline (7). White solid (50% yield); mp 80–82 °C; ¹H-NMR (DMSO-*d*₆) δ 8.86 (s, 1H), 8.25 (d, *J* = 8.0 Hz, 1H), 8.06–8.03 (m, 1H), 8.00–7.98 (m, 1H), 7.81–7.78 (m, 1H), 7.47–7.44 (m, 1H), 7.24–7.22 (m, 2H), 7.14–7.11 (m, 1H), 3.80 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.3, 159.7, 153.5, 147.8, 134.6, 130.3, 128.5, 128.3, 127.8, 127.5, 123.5, 122.4, 120.9, 115.7, 55.3; HRMS (ESI), *m/z*, 269.0746 [MH⁺], calcd for C₁₅H₁₃N₂OS, 269.0749.

4-(4-Methoxyphenylthio)quinazoline (**8**). White solid (86% yield); mp 125–128 °C; ¹H-NMR (DMSO-*d*₆) δ 8.82 (s, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 8.04–8.01 (m, 1H), 7.98–7.96 (m, 1H), 7.80–7.77 (m, 1H), 7.57–7.54 (m, 2H), 7.10–7.09 (m, 2H), 3.84 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 171.1, 160.7, 153.5, 147.7, 137.6, 134.6, 128.4, 128.3, 123.6, 122.3, 116.6, 115.3, 55.4; HRMS (ESI), *m/z*, 269.0739 [MH⁺], calcd for C₁₅H₁₃N₂OS, 269.0749.

4-(2-Chlorophenylthio)quinazoline (**9**). White solid (94% yield); mp 124–126 °C; ¹H-NMR (DMSO-*d*₆) δ 8.85 (s, 1H), 8.29 (d, *J* = 8.0 Hz, 1H), 8.08–8.05 (m, 1H), 8.02–8.00 (m, 1H), 7.84–7.80 (m, 2H), 7.74–7.72 (m, 1H), 7.62–7.59 (m, 1H), 7.52–7.49 (m, 1H); ¹³C-NMR (DMSO-*d*₆) δ 168.9, 153.4, 147.9, 138.8, 138.4, 134.7, 132.2, 130.3, 128.51, 128.47, 128.2, 125.9, 123.6, 122.3; HRMS (ESI), *m/z*, 273.0244 [MH⁺], calcd for C₁₄H₁₀ClN₂S, 273.0253.

5589

4-(3-Chlorophenylthio)quinazoline (**10**). White solid (66% yield); mp 125–126 °C; ¹H-NMR (DMSO-*d*₆) δ 8.86 (s, 1H), 8.23 (d, *J* = 8.0 Hz, 1H), 8.04–8.03 (m, 1H), 8.00–7.98 (m, 1H), 7.81–7.76 (m, 2H), 7.65–7.61 (m, 2H), 7.58–7.55 (m, 1H); ¹³C-NMR (DMSO-*d*₆) δ 169.7, 153.4, 147.9, 135.0, 134.7, 134.4, 133.6, 131.1, 129.9, 128.8, 128.5, 128.4, 123.5, 122.3; HRMS (ESI), *m/z*, 273.0243 [MH⁺], calcd for C₁₄H₁₀ClN₂S, 273.0253.

4-(4-Chlorophenylthio)quinazoline (11). White solid (91% yield); mp 133–134 °C; ¹H-NMR (DMSO-*d*₆) δ 8.85 (s, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 8.07–8.03 (m, 1H), 8.00–7.99 (m, 1H), 7.82–7.79 (m, 1H), 7.70–7.67 (m, 2H), 7.62–7.60 (m, 2H); ¹³C-NMR (DMSO-*d*₆) δ 169.9, 153.4, 147.8, 137.5, 135.0, 134.7, 129.6, 128.5, 128.4, 125.5, 123.5, 122.3; HRMS (ESI), *m*/*z*, 273.0240 [MH⁺], calcd for C₁₄H₁₀ClN₂S, 273.0253.

5-*Methyl-4-(phenylthio)quinazoline* (**12**). White solid (54% yield); mp 131–133 °C; ¹H-NMR (DMSO-*d*₆) δ 8.66 (s, 1H), 7.85–7.82 (m, 1H), 7.80–7.78 (m, 1H), 7.62–7.57 (m, 3H), 7.55–7.52 (m, 3H), 3.07 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 171.3, 152.2, 150.2, 135.9, 135.4, 133.4, 130.8, 129.7, 129.5, 128.2, 127.0, 123.4, 24.7; HRMS (ESI), *m/z*, 253.0790 [MH⁺], calcd for C₁₅H₁₃N₂S, 253.0799.

6-*Methyl-4-(phenylthio)quinazoline* (**13**). White solid (60% yield); mp 100–102 °C; ¹H-NMR (DMSO-*d*₆) δ 8.83 (s, 1H), 8.00 (s, 1H), 7.89 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.67–7.65 (m, 2H), 7.52–7.51 (m, 3H), 2.62 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.4, 153.3, 146.9, 137.9, 136.0, 135.8, 129.7, 129.4, 128.6, 127.4, 123.3, 122.7, 21.8; HRMS (ESI), *m/z*, 253.0796 [MH⁺], calcd for C₁₅H₁₃N₂S, 253.0799.

8-*Methyl-4-(phenylthio)quinazoline* (14). White solid (64% yield); mp 98–100 °C; ¹H-NMR (DMSO-*d*₆) δ 8.84 (s, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.85 (d, *J* = 7.0 Hz, 1H), 7.65–7.62 (m, 3H), 7.54–7.53 (m, 3H), 2.66 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.3, 152.6, 146.8, 136.7, 135.7, 134.2, 129.7, 129.5, 127.7, 126.8, 122.2, 121.1, 17.0; HRMS (ESI), *m/z*, 253.0789 [MH⁺], calcd for C₁₅H₁₃N₂S, 253.0799.

5-*Chloro-4-(phenylthio)quinazoline* (**15**). White solid (51% yield); mp 133–134 °C; ¹H-NMR (CDCl₃) δ 8.73 (s, 1H), 7.91–7.89 (m, 1H), 7.74–7.68 (m, 2H), 7.60–7.58 (m, 2H), 7.51–7.50 (m, 3H); ¹³C-NMR (CDCl₃) δ 172.5, 153.2, 151.3, 135.9, 132.7, 130.6, 129.9, 129.7, 129.4, 129.3, 128.5, 122.6; HRMS (ESI), *m/z*, 273.0244 [MH⁺], calcd for C₁₄H₁₀ClN₂S, 273.0253.

6-*Chloro-4-(phenylthio)quinazoline* (**16**). White solid (79% yield); mp 103–105 °C; ¹H-NMR (CDCl₃) δ 8.86 (s, 1H), 8.22 (d, J = 2.0 Hz, 1H), 7.93 (d, J = 9.0 Hz, 1H), 7.83–7.81 (m, 1H), 7.66–7.64 (m, 2H), 7.53–7.51 (m, 3H); ¹³C-NMR (CDCl₃) δ 170.7, 154.0, 146.9, 135.8, 134.8, 133.3, 130.5, 130.0, 129.5, 126.7, 123.8, 122.9; HRMS (ESI), *m/z*, 273.0241 [MH⁺], calcd for C₁₄H₁₀ClN₂S, 273.0253.

7-*Chloro-4-(phenylthio)quinazoline* (17). White solid (72% yield); mp 142–143 °C; ¹H-NMR (DMSO-*d*₆) δ 8.85 (s, 1H), 8.29 (d, *J* = 9.0 Hz, 1H), 8.07 (d, *J* = 2.0 Hz, 1H), 7.83–7.81 (m, 1H), 7.67–7.66 (m, 2H), 7.57–7.55 (m, 3H); ¹³C-NMR (DMSO-*d*₆) δ 170.7, 154.5, 148.6, 139.2, 135.7, 130.0, 129.6, 128.9, 127.3, 126.1, 125.7, 121.0; HRMS (ESI), *m/z*, 273.0255 [MH⁺], calcd for C₁₄H₁₀ClN₂S, 273.0253.

4-Phenoxyquinazoline (**18**). White solid (75% yield); mp 123–125 °C; ¹H-NMR (CDCl₃) δ 8.80 (s, 1H), 8.42–8.40 (m, 1H), 8.03 (d, *J* = 8.5 Hz, 1H), 7.96–7.94 (m, 1H), 7.69 (t, *J* =1.0 Hz, 1H), 7.54–7.50 (m, 2H), 7.37–7.35 (m, 1H), 7.30–7.28 (m, 2H); ¹³C-NMR (CDCl₃) δ 167.0, 154.4, 152.4, 151.7, 134.2, 129.8, 128.0, 127.6, 126.1, 123.7, 121.9, 116.5; HRMS (ESI), *m/z*, 223.0868 [MH⁺], calcd for C₁₄H₁₁N₂O, 223.0871.

4-(m-Tolyloxy)quinazoline (**19**). White solid (52% yield); mp 100–101 °C; ¹H-NMR (CDCl₃) δ 8.81 (s, 1H), 8.41–8.39 (m, 1H), 8.03 (d, *J* = 8.5 Hz, 1H), 7.95–7.92 (m, 1H), 7.70–7.67 (m, 1H), 7.41–7.38 (d, *J* = 7.5 Hz, 1H), 7.17–7.08 (m, 3H), 2.44 (s, 3H); ¹³C-NMR (CDCl₃) δ 167.1, 154.4, 152.3, 151.6, 140.1, 134.1, 129.5, 127.9, 127.6, 126.9, 123.7, 122.4, 118.8, 116.5, 21.4; HRMS (ESI), *m/z*, 237.1025 [MH⁺], calcd for C₁₅H₁₃N₂O, 237.1028.

4-(2-Chlorophenoxy)quinazoline (**20**). White solid (73% yield); mp 118–119 °C; ¹H-NMR (CDCl₃) δ 8.78 (s, 1H), 8.46–8.45 (m, 1H), 8.05 (d, *J* = 8.5 Hz, 1H), 7.98–7.96 (m, 1H), 7.74–7.72 (m, 1H), 7.57–7.56 (m, 1H), 7.43–7.41 (m, 1H), 7.38–7.36 (m, 1H), 7.34–7.32 (m, 1H); ¹³C-NMR (CDCl₃) δ 166.2, 154.1, 151.9, 148.6, 134.3, 130.7, 128.1, 128.0, 127.8, 127.31, 127.26, 124.1, 123.7, 116.1; HRMS (ESI), *m/z*, 257.0479 [MH⁺], calcd for C₁₄H₁₀ClN₂O, 257.0482.

4-(4-Chlorophenoxy)quinazoline (**21**). White solid (51% yield); mp 105–108 °C; ¹H-NMR (CDCl₃) δ 8.79 (s, H), 8.39 (d, *J* = 8.0 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.97–7.94 (m, 1H), 7.72–7.69 (m, 1H), 7.49–7.46 (m, 2H), 7.28–7.23 (m, 2H); ¹³C-NMR (CDCl₃) δ 116.8, 154.1, 151.8, 150.9, 134.3, 131.5, 129.9, 128.0, 127.8, 123.5, 123.3, 116.3; HRMS (ESI), *m/z*, 257.0469 [MH⁺], calcd for C₁₄H₁₀ClN₂O, 257.0482.

5-Methyl-4-phenoxyquinazoline (**22**). White solid (53% yield); mp 73–75 °C; ¹H-NMR (CDCl₃) δ 8.70 (s, 1H), 7.86 (d, *J* = 8.5 Hz, 1H), 7.77 (t, *J* = 7.5 Hz, 1H), 7.53–7.50 (m, 2H), 7.45 (d, *J* = 7.5 Hz, 1H), 7.36–7.33 (m, 1H), 7.28–7.25 (m, 2H), 3.00 (s, 3H); ¹³C-NMR (CDCl₃) δ 168.0, 153.7, 153.4, 152.3, 136.7, 133.4, 129.9, 129.8, 126.1, 125.9, 122.0, 116.3, 24.1; HRMS (ESI), *m/z*, 237.1021 [MH⁺], calcd for C₁₅H₁₃N₂O, 237.1028.

6-*Chloro-4-phenoxyquinazoline* (**23**). White solid (70% yield); mp 94–97 °C; ¹H-NMR (CDCl₃) δ 8.77 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 7.86–7.83 (m, 1H), 7.52–7.49 (m, 2H), 7.36–7.33 (m, 1H), 7.29–7.27 (m, 2H); ¹³C-NMR (CDCl₃) δ 166.1, 154.4, 152.1, 150.1, 134.9, 133.2, 129.8, 129.6, 126.2, 122.7, 121.7, 117.1; HRMS (ESI), *m/z*, 257.0471 [MH⁺], calcd for C₁₄H₁₀ClN₂O, 257.0482.

7-*Chloro-4-phenoxyquinazoline* (**24**). White solid (70% yield); mp 190–192 °C; ¹H-NMR (CDCl₃) δ 8.78 (s, 1H), 8.35 (d, *J* = 8.5 Hz, 1H), 8.03 (d, *J* = 2.0 Hz, 1H), 7.65–7.63 (m, 1H), 7.53–7.50 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.29–7.27 ppm (m, 2H); ¹³C-NMR (CDCl₃) δ 166.9, 155.5, 152.4, 152.2, 140.5, 129.8, 128.7, 127.2, 126.2, 125.2, 121.8, 114.9; HRMS (ESI), *m/z*, 257.0471 [MH⁺], calcd for C₁₄H₁₀ClN₂O, 257.0482.

4-Ethoxyquinazoline (**25**). White solid (54% yield); mp 31–33 °C; ¹H-NMR (CDCl₃) δ 8.80 (s, 1H), 8.19–8.18 (m, 1H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.84–7.81 (m, 1H), 7.58–7.54 (m, 1H), 4.64 (q, *J* = 7.0 Hz,

2H), 1.53 (t, J = 7.0 Hz, 3H); ¹³C-NMR (CDCl₃) δ 166.7, 154.5, 150.9, 133.4, 127.7, 126.9, 123.6, 116.8, 63.1, 14.4; HRMS (ESI), m/z, 175.0873 [MH⁺], calcd for C₁₀H₁₁N₂O, 175.0871.

4-Ethoxy-5-methylquinazoline (**26**). White solid (33% yield); mp 66–69 °C; ¹H-NMR (CDCl₃) δ 8.72 (s, 1H), 7.77 (d, *J* = 8.5 Hz, 1H), 7.67 (t, *J* = 7.5 Hz, 1H), 7.33 (d, *J* = 7.5 Hz, 1H), 4.61 (q, *J* = 7.0 Hz, 2H), 2.86 (s, 3H), 1.54 (t, *J* = 7.0 Hz, 3H); ¹³C-NMR (CDCl₃) δ 167.8, 153.8, 152.6, 136.9, 132.7, 129.3, 125.8, 116.4, 63.1, 24.0, 14.4; HRMS (ESI), *m/z*, 189.1034 [MH⁺], calcd for C₁₁H₁₃N₂O, 189.1028.

4-Ethoxy-8-methylquinazoline (**27**). White solid (67% yield); mp 31–32 °C; ¹H-NMR (CDCl₃) δ 8.84 (s, 1H), 8.04–8.02 (m, 1H), 7.66 (d, *J* = 7.5 Hz, 1H), 7.44 (t, *J* = 8.0 Hz, 1H), 4.63 (q, *J* = 7.0 Hz, 2H), 2.73 (s, 3H), 1.52 (t, *J* = 7.0 Hz, 3H); ¹³C-NMR (CDCl₃) δ 166.9, 153.4, 150.0, 135.9, 133.5, 126.4, 121.2, 116.6, 62.9, 17.6, 14.3; HRMS (ESI), *m/z*, 189.1023 [MH⁺], calcd for C₁₁H₁₃N₂O, 189.1028.

7-*Chloro-4-ethoxyquinazoline* (**28**). White solid (64% yield); mp 87–88 °C; ¹H-NMR (CDCl₃) δ 8.76 (s, 1H), 8.08 (d, *J* = 9.0 Hz, 1H), 7.90 (d, *J* = 1.5 Hz, 1H), 7.49–7.47 (m, 1H), 4.62 (q, *J* = 7.0 Hz, 2H), 1.51 (t, *J* = 7.0 Hz, 3H); ¹³C-NMR (CDCl₃) δ 166.6, 155.5, 151.6, 139.6, 127.8, 126.9, 125.0, 115.0, 63.3, 14.3; HRMS (ESI), *m/z*, 209.0479 [MH⁺], calcd for C₁₀H₁₀ClN₂O, 209.0482.

4-Propoxyquinazoline (**29**). White solid (48% yield); mp 190–192 °C; ¹H-NMR (CDCl₃) δ 8.79 (s, 1H), 8.19-8.17 (m, 1H), 7.92 (d, *J* = 8.5 Hz, 1H), 7.83–7.80 (m, 1H), 7.57–7.53 (m, 1H), 4.52 (t, *J* = 6.5 Hz, 2H), 1.95–1.91 (m, 2H), 1.10 (t, *J* = 7.5 Hz, 3H); ¹³C-NMR (CDCl₃) δ 166.8, 154.4, 150.9, 133.4, 127.6, 126.9, 123.5, 116.7, 68.7, 22.1, 10.5; HRMS (ESI), *m/z*, 189.1023 [MH⁺], calcd for C₁₁H₁₃N₂O, 189.1028.

4. Conclusions

In summary, we have successfully developed an HCCP-mediated direct formation of thioethers (4-arylthioquinazolines) from quinazolin-4(3H)-ones and thiophenols in moderate to excellent yields. This method has also been utilized to prepare quinazoline ethers, including 4-aryloxyquinazolines and 4-alkoxyquinazolines, using phenols and sodium alkoxides as the nucleophiles. This direct formation of quinazoline (thio)ethers is mild, convenient, and suitable for a wide range of less expensive nucleophiles. This methodology would facilitate the syntheses of 4-arylthioquinazoline and 4-aryloxyquinazoline derivatives in medicinal chemistry.

Acknowledgments

The authors gratefully acknowledge the financial support of the National Natural Science Foundations of China (NSFC 21146001), and the Key Science and Technology Innovation Team of Zhejiang Province (2009R09002-04).

Conflict of Interest

The authors declare no conflict of interest.

References

- Hori, M.; Iemura, R.; Hara, H.; Ozaki, A.; Sukamoto, T.; Ohtaka, H. Novel 4-phenoxy-2-(1-piperazinyl)quinazolines as potent anticonvulsive and antihypoxic agents. *Chem. Pharm. Bull.* 1990, 38, 681–687.
- 2. Havera, H.J.; Vidrio, H.J. Derivatives of 1,3-disubstituted 2,4(1*H*,3*H*)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents. *J. Med. Chem.* **1979**, *22*, 1548–1550.
- Chao, Q.; Deng, L.; Shih, H.; Leoni, L.M.; Genini, D.; Carson, D.A.; Cottam, H.B. Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor α. J. Med. Chem. 1999, 42, 3860–3873.
- Kung, P.P.; Casper, M.D.; Cook, K.L.; Wilson-Lingardo, L.; Risen, L.M.; Vickers, T.A.; Ranken, R.; Blyn, L.B.; Wyatt, J.R.; Cook, P.D.; *et al.* Structure–activity relationships of novel 2-substituted quinazoline antibacterial agents. *J. Med. Chem.* 1999, *42*, 4705–4713.
- Liverton, N.J.; Armstrong, D.J.; Claremon, D.A.; Remy, D.C.; Bardwin, J.J.; Lynch, R.J.; Zhang, G.; Gould, R.J. Nonpeptide glycoprotein IIb/IIIa inhibitors: Substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 483–486.
- 6. Brunton, S.A.; Stibbard, J.H.A.; Rubin, L.L.; Kruse, L.I.; Guicherit, O.M.; Boyd, E.A.; Price, S. Potent inhibitors of the Hedgehog signaling pathway. *J. Med. Chem.* **2008**, *51*, 1108–1110.
- Smits, R.A.; de Esch, I.J.P.; Zuiderveld, O.P.; Broeker, J.; Sansuk, K.; Guaita, E.; Coruzzi, G.; Adami, M.; Haaksma, E.; Leurs, R. Discovery of quinazolines as histamine H₄ receptor inverse agonists using a scaffold hopping approach. *J. Med. Chem.* 2008, *51*, 7855–7865.
- 8. Sirisoma, N; Pervin, A.; Zhang, H.; Jiang, S.C.; Willardsen, J.A.; Anderson, M.B.; Mather, G.; Pleiman, C.M.; Kasibhatla, S.; Tseng, B.; *et al.* Discovery of *N*-(4-methoxyphenyl)-*N*,2-dimethylquinazolin-4-amine, a potent apoptosis inducer and efficacious anticancer agent with high blood brain barrier penetration. *J. Med. Chem.* **2009**, *52*, 2341–2351.
- Zeng, Z.-S.; He, Q.-Q.; Liang, Y.-H.; Feng, X.-Q.; Chen, F.-E.; Clercq, E.D.; Balzarini, J. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. *Bioorg. Med. Chem.* 2010, *18*, 5039–5047.
- 10. Nakamura, H.; Onagi, S. Synthesis and biological evaluation of allenic quinazolines using palladium-catalyzed hydride-transfer reaction. *Tetrahedron Lett.* **2006**, *47*, 2539–2542.
- Castera-Ducros, C.; Azas, N.; Verhaeghe, P.; Hutter, S.; Garrigue, P.; Dumetre, A.; Mbatchi, L.; Laget, M.; Remusat, V.; Sifredi, F.; *et al.* Targeting the human malaria parasite Plasmodium falciparum: *In vitro* identification of a new antiplasmodial hit in 4-phenoxy-2trichloromethylquinazoline series. *Eur. J. Med. Chem.* 2011, *46*, 4184–4191.
- Holladay, M.W.; Campbell, B.T.; Rowbottom, M.W.; Chao, Q.; Sprankle, K.G.; Lai, A.G.; Abraham, S.; Setti, E.; Faraoni, R.; Tran, L.; *et al.* 4-Quinazolinyloxy-diaryl ureas as novel BRAF^{V600E} inhibitors. *Bioorg. Med. Chem. Lett.* 2011, *21*, 5342–5346.
- Rowbottom, M.W.; Faraoni, R.; Chao, Q.; Campbell, B.T.; Lai, A.G.; Setti, E.; Ezawa, M.; Sprankle, K.G.; Abraham, S.; Tran, L.; *et al.* Identification of 1-(3-(6,7-dimethoxyquinazolin-4yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. *J. Med. Chem.* 2012, *55*, 1082–1105.

- Ple, P.A.; Jung, F.; Ashton, S.; Hennequin, L.; Laine, R.; Morgentin, R.; Pasquet, G.; Taylor, S. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. *Bioorg. Med. Chem. Lett.* 2012, *22*, 262–266.
- Yang, S.; Li, Z.; Jin, L.H.; Song, B.A.; Liu, G.; Chen, J.; Chen, Z.; Hu, D.Y.; Xue, W.; Xu, R.Q. Synthesis and bioactivity of 4-alkyl(aryl)thioquinazoline derivatives. *Bioorg. Med. Chem. Lett.* 2007, 17, 2193–2196.
- Verhaeghe, P.; Dumetre, A.; Castera-Ducros, C.; Hutter, S.; Laget, M.; Fersing, C.; Prieri, M.; Yzombard, J.; Sifredi, F.; Rault, S.; *et al.* 4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum. *Bioorg. Med. Chem. Lett.* 2011, *21*, 6003–6006.
- Garofalo, A.; Goossens, L.; Baldeyrou, B.; Lemoine, A.; Ravez, S.; Six, P.; David-Cordonnier, M.-H.; Bonte, J.-P.; Depreux, P.; Lansiaux, A.; *et al.* Design, synthesis, and DNA-binding of *N*-alkyl(anilino)quinazoline derivatives. *J. Med. Chem.* **2010**, *53*, 8089–8103.
- 18. Harris, C.S.; Hennequin, L.F.; Willerval, O. Three-point variation of a gefinitib quinazoline core. *Tetrahedron Lett.* **2009**, *50*, 1600–1602.
- 19. Sreedhar, B.; Reddy, P.S.; Reddy, M.A. Catalyst-free and base-free water-promoted SNAr reaction of heteroaryl halides with thiols. *Synthesis* **2009**, 1732–1738.
- 20. Wan, Z.K.; Wacharasindhu, S.; Binnun, E.; Mansour, T. An efficient direct amination of cyclic amides and cyclic ureas. *Org. Lett.* **2006**, *8*, 2425–2428.
- Wan, Z.K.; Wacharasindhu, S.; Levins, C.G.; Lin, M.; Tabei, K.; Mansour, T.S. The scope and mechanism of phosphonium-mediated S_NAr reactions in heterocyclic amidesand ureas. *J. Org. Chem.* 2007, *72*, 10194–10210.
- 22. Shen, Z.L.; Hong, Y.M.; He, X.F.; Mo, W.M.; Hu, B.X.; Sun, N.; Hu, X.Q. Switching the chemoselectivity in the amination of 4-chloroquinazolines with aminopyrazoles. *Org. Lett.* **2010**, *12*, 552–555.
- Shen, Z.L.; He, X.F.; Hong, Y.M.; Hu, X.Q.; Mo, W.M.; Hu, B.X.; Sun, N. One-pot synthesis of 4-aminoquinazolines by hexamethyldisilazane-mediated reaction of quinazolin-4(3H)-ones with amines. Synth. Commun. 2011, 41, 3644–3653.
- 24. Shen, Z.L.; He, X.F.; Dai, J.L.; Mo, W.M.; Hu, B.X.; Sun, N.; Hu, X.Q. An efficient HCCP-mediated direct amination of quinazolin-4(3*H*)-ones. *Tetrahedron* 2011, 67, 1665–1672.

Sample Availability: Samples of the compounds 3–17 are available from the authors.

 \bigcirc 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).